Efficacy and safety of sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir for hepatitis C in Korea: a Phase 3b study

Background/Aims Despite the availability of direct-acting antivirals (DAAs) for chronic hepatitis C virus (HCV) infection in Korea, need remains for pangenotypic regimens that can be used in the presence of hepatic impairment, comorbidities, or prior treatment failure. We investigated the efficacy a...

Descripció completa

Dades bibliogràfiques

Autors principals:	Jeong Heo, Yoon Jun Kim, Sung Wook Lee, Youn-Jae Lee, Ki Tae Yoon, Kwan Soo Byun, Yong Jin Jung, Won Young Tak, Sook-Hyang Jeong, Kyung Min Kwon, Vithika Suri, Peiwen Wu, Byoung Kuk Jang, Byung Seok Lee, Ju-Yeon Cho, Jeong Won Jang, Soo Hyun Yang, Seung Woon Paik, Hyung Joon Kim, Jung Hyun Kwon, Neung Hwa Park, Ju Hyun Kim, In Hee Kim, Sang Hoon Ahn, Young-Suk Lim
Format:	Artigo
Idioma:	Inglês
Publicat:	The Korean Association of Internal Medicine 2023-07-01
Col·lecció:	The Korean Journal of Internal Medicine
Matèries:	direct-acting antiviral decompensated cirrhosis ns5a inhibitor polymerase inhibitor protease inhibitor
Accés en línia:	http://kjim.org/upload/kjim-2022-252.pdf
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!